ONC BeOne Medicines Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1651308 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY32.9%
TTM net income YoY1,235.6%
TTM EPS YoY1,400.0%
Revenue 3-yr CAGR44.2%
Net income 3-yr CAGR—
Margins
Gross margin89.4%
Operating margin17.8%
Net margin13.9%
FCF margin21.9%
EBITDA margin20.2%
Returns
ROE18.4%
ROA10.5%
ROIC (approx.)158.2%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets41.1%
Debt / equity0.18x
Current ratio3.55x
Interest coverage8.31x
Cash quality & payout
Operating cash flow / net income1.74x
Accruals ratio-7.7%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.89B | $1.71B | $1.51B | $1.50B | $1.41B | $1.32B | $1.12B | $1.13B |
| Gross profit | $1.67B | $1.53B | $1.35B | $1.36B | $1.22B | $1.15B | $952.28M | $967.26M |
| R&D expense | $660.78M | $612.28M | $541.22M | $615.42M | $523.66M | $524.90M | $481.89M | $542.01M |
| SG&A expense | $593.46M | $593.21M | $555.10M | $555.29M | $529.00M | $537.91M | $459.29M | $504.68M |
| Operating income | $418.68M | $325.05M | $249.90M | $185.03M | $163.11M | $87.89M | $11.10M | -$79.42M |
| Interest expense | $42.41M | $39.74M | $32.89M | $26.87M | $16.36M | $8.00M | $7.00M | $6.95M |
| Pretax income | $410.36M | $312.46M | $259.21M | $149.24M | $147.16M | $99.55M | $20.90M | -$85.35M |
| Income tax | $25.65M | $75.45M | $31.86M | $82.74M | $22.32M | $5.23M | $19.63M | $66.53M |
| Net income | $384.71M | $237.01M | $227.36M | $66.50M | $124.84M | $94.32M | $1.27M | -$151.88M |
| EBITDA | $456.00M | $363.95M | $291.05M | $221.02M | $198.84M | $117.74M | $43.91M | -$29.18M |
| EPS (basic) | 0.26 | 0.16 | 0.16 | — | 0.09 | 0.07 | 0.00 | — |
| EPS (diluted) | 0.25 | 0.16 | 0.15 | — | 0.08 | 0.06 | 0.00 | — |
| Weighted avg. shares (diluted) | 1.52B | 1.51B | 1.51B | — | 1.49B | 1.46B | 1.45B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.78B | $5.10B | $4.79B | $4.55B | $4.04B | $2.76B | $2.52B | $2.64B |
| Receivables | $1.09B | $1.06B | $938.02M | $865.08M | $863.28M | $770.78M | $717.24M | $676.28M |
| Inventory | $807.92M | $732.60M | $681.59M | $608.23M | $531.69M | $502.87M | $494.66M | $494.99M |
| Current assets | $7.93B | $7.22B | $6.60B | $6.23B | $5.66B | $4.31B | $3.90B | $3.99B |
| PP&E, net | $1.65B | $1.64B | $1.64B | $1.64B | $1.63B | $1.62B | $1.60B | $1.58B |
| Intangibles | $37.92M | $60.96M | $61.68M | $62.70M | $63.58M | $64.89M | $50.14M | $51.09M |
| Total assets | $9.88B | $9.18B | $8.55B | $8.19B | $7.63B | $6.30B | $5.84B | $5.92B |
| Current liabilities | $2.23B | $2.12B | $1.81B | $1.83B | $2.37B | $2.21B | $1.98B | $2.21B |
| Short-term debt | $248.86M | $190.90M | $116.14M | $57.29M | $813.30M | $808.39M | $763.47M | $851.53M |
| Long-term debt | $825.22M | $882.16M | $962.51M | $961.91M | — | $146.09M | $160.16M | $166.48M |
| Total debt | $1.07B | $1.07B | $1.08B | $1.02B | — | $954.49M | $923.63M | $1.02B |
| Total liabilities | $4.06B | $4.00B | $3.79B | $3.83B | $3.50B | $2.53B | $2.34B | $2.59B |
| Shareholders' equity | $5.82B | $5.17B | $4.76B | $4.36B | $4.13B | $3.77B | $3.50B | $3.33B |
| Net debt | -$4.71B | -$4.02B | -$3.71B | -$3.53B | — | -$1.80B | -$1.59B | -$1.62B |
| Shares outstanding | 1.48B | 1.47B | 1.44B | 1.44B | 1.44B | 1.43B | 1.40B | 1.39B |
| Cash flow statement | ||||||||
| Operating cash flow | $508.71M | $462.82M | $201.34M | $417.35M | $402.55M | $263.60M | $44.08M | $75.16M |
| Capital expenditure | $35.17M | $27.48M | $40.79M | $37.52M | $48.08M | $43.83M | $56.41M | $92.48M |
| Free cash flow | $473.53M | $435.34M | $160.55M | $379.82M | $354.47M | $219.77M | -$12.32M | -$17.32M |
| Investing cash flow | -$35.76M | -$49.35M | -$45.51M | -$38.34M | -$49.27M | -$66.61M | -$121.94M | -$93.61M |
| Financing cash flow | $102.19M | -$6.05M | $68.63M | $96.93M | $961.27M | $35.02M | -$33.78M | -$4.52M |
| Depreciation & amortization | $37.32M | $38.91M | $41.14M | $35.98M | $35.73M | $29.85M | $32.80M | $50.25M |
| Stock-based compensation | $132.62M | $137.47M | $123.36M | $123.76M | $140.79M | $150.55M | $95.48M | $107.62M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.